ClinicalTrials.gg
Active, not recruitingNCT06982859Updated Oct 6, 2026

A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus

A Phase 1 interventional study of Retatrutide and Semaglutide in Diabetes Mellitus and Insulin Sensitivity, sponsored by Eli Lilly and Company. Active, not recruiting at 1 site in Germany. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

Updated Oct 6, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
95
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 48 studies in Diabetes Mellitus by Eli Lilly and Company — none open to participants now, 4 under way, 1 of them phase 3. Diabetes Mellitus · Eli Lilly and Company.

Planned enrollment
36th of 47
95 · median 299
Started
2025
with 2 others
Phase 1
5 of 48
none open now
Registered
48th of 48
by date

Among the 48 studies in Diabetes Mellitus by Eli Lilly and Company, this one is the 36th largest by planned enrollment of the 47 interventional ones that give a count, is one of 3 that started in 2025, is one of 5 in phase 1, and was the 48th registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

None of the 48 studies in Diabetes Mellitus by Eli Lilly and Company is open now. The open studies under Diabetes Mellitus, anywhere →

Who these studies take

Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 48 studies in Diabetes Mellitus by Eli Lilly and Company as a file.
02

Study summary

The primary objective of Study GZQG is to compare the effect of retatrutide and placebo on total clamp disposition index (cDI) after 28 weeks of treatment.

03

Conditions studied

  • Diabetes Mellitus
  • Insulin Sensitivity
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have been diagnosed with Type 2 Diabetes Mellitus (T2DM) for at least 6 months prior to screening.
  • Treated with diet and exercise and metformin daily, with or without other allowed oral antihyperglycaemia medications (OAMs), 3 months prior to screening. Allowed OAMs are dipeptidyl peptidase-4 inhibitors (DPP-IV) inhibitors, sodium/glucose cotransporter 2 (SGLT2) inhibitors, glinides, and sulfonylureas.
  • Have a value at screening of:

    • 6.5% and ≤ 9.5 % if on metformin with or without SGLT2 inhibitors, or
    • 6% and ≤8.5% if on metformin in combination with allowed OAMs that require washout.
  • Have venous access sufficient to allow for blood sampling as per the protocol.
  • Have clinical laboratory test results within normal reference range for the population or investigative site or results with acceptable deviations that are judged to be not by the investigator.
  • Have a (BMI) between 25 kilograms per meter squared (kg/m²) and 45 kg/m², both inclusive, at screening.
  • Have had a stable body weight that is less than 5% change during the 3-month period prior to screening.

Exclusion criteria

Exclusion Criteria:

  • Have Type 1 Diabetes Mellitus (T1DM)
  • Have had more than 1 episode of severe hypoglycaemia, as defined by the American Diabetes Association criteria, within 6 months before screening or a history of hypoglycaemia unawareness or poor recognition of hypoglycaemic symptoms; any participant that cannot communicate an understanding of hypoglycaemic symptoms and the appropriate treatment of hypoglycaemia prior to the first dose of study drug should also be excluded.
  • Have had 1 or more episodes of ketoacidosis or hyperosmolar state/coma requiring hospitalisation within the 6 months prior to screening.
  • Are currently receiving, planning to receive, or in need of treatment, that is, intravitreal injections of Vascular Endothelial Growth Factor inhibitor or , focal/grid macular laser surgery, panretinal photocoagulation, or vitrectomy for diabetic retinopathy at screening.
  • Have impaired renal estimated \<60.0 mL/min/1.73 m² calculated by Chronic Kidney Disease-Epidemiology (2021).
  • Have acute or chronic pancreatitis or a history of acute idiopathic pancreatitis.
  • Have elevations in:

    • serum (AST) >2.5X the (ULN)
    • serum alanine aminotransferase (ALT) >2.5X ULN
    • total level (TBL) >1.5X ULN (except, participants with Gilbert's syndrome), or
    • Alkaline phosphatase (ALP) level ≥1.5X ULN
  • Show evidence of possible chronic or active , including hepatitis B core antibody and/or hepatitis B surface antigen positivity.
  • Have a positive virus (HCV) antibody (Ab) test. Participants with a positive HCV Ab test at screening can be included only if a confirmatory HCV ribonucleic acid (RNA) test is negative.
  • Have a known gastric emptying abnormality, have undergone gastric bypass (bariatric) surgery or restrictive bariatric surgery or chronically take drugs that directly affect GI motility.
  • Have had within 3 months prior to screening:

    • acute myocardial infarction
    • congestive heart failure (NYHA) class III or IV, and/or
    • cerebrovascular accident [stroke]
    • coronary artery revascularisation
    • hospitalization hospitalisation for unstable angina
    • hospitalization hospitalisation due to congestive heart failure.
  • Have a history of additional risk factors for Torsades de Pointes (for example, heart failure, hypokalaemia, family history of Long Syndrome), as judged by the investigator.
  • Have a 12-lead abnormality at screening that, in the opinion of the investigator, increases the risks associated with participating in the study or may confound electrocardiogram (ECG) data analysis.
  • Have a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome Type 2 (MEN 2).
  • Have an active or untreated or have been in remission from a clinically significant malignancy for \<5 years prior to screening. Exceptions:

    • basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of disease for 3 years
    • cervical carcinoma in situ, with no evidence of recurrence within the 5 years prior to baseline, or
    • in situ prostate cancer.
  • Have, in the opinion of the investigator, evidence of significant, uncontrolled endocrine abnormality, for example, thyrotoxicosis or adrenal crisis.
  • Have a prior or planned surgical treatment for obesity.
  • Have a prior or planned endoscopic and/or device-based therapy for obesity.
  • Have taken any glucose-lowering medications other than metformin, DPP IV inhibitors, sulfonylureas and/or SGLT-2 inhibitors, regardless of the indication for use, any time within the 3 months prior to screening.
  • Have taken prescribed or over-the-counter (OTC) medications, either approved or unapproved, or alternative remedies, including herbal or nutritional supplements, intended to promote body weight reduction, within 3 months prior to screening.
  • Have evidence of (HIV) infection and/or positive human HIV antibodies.
  • Have a calcitonin level at screening of ≥35.0 nanograms per liter (ng/L), [≥35.0 picograms per milliliter (pg/mL)].
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
95 participants (estimated)

Study arms

  • Experimental
    Retatrutide

    Retatrutide administered subcutaneously (SC).

    Drug: Retatrutide

  • Active comparator
    Semaglutide

    Semaglutide administered SC.

    Drug: Semaglutide

  • Placebo comparator
    Placebo

    Placebo administered SC.

    Drug: Placebo

Interventions

  • Administered SC

    Also known as: LY3437943

  • Administered SC

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Total Clamp Disposition Index (cDI) for Comparison of Retatrutide With Placebo

    Change from baseline in total cDI for comparison of retatrutide with placebo

    Time frame: Baseline, Week 28

Secondary outcomes

  1. Change from Baseline in cDI for Comparison Between Retatrutide and Semaglutide

    Change from baseline in total cDI for comparison between retatrutide and semaglutide

    Time frame: Baseline, Week 28

  2. Change from Baseline in Hyperinsulinemic Euglycemic Clamp M-value

    Change from baseline in hyperinsulinemic euglycemic clamp M-value

    Time frame: Baseline, Week 28

  3. Change from Baseline in First Phase Incremental Insulin Secretion Rate (ISR)

    Change from baseline in first phase ISR.

    Time frame: Baseline, Week 28

  4. Change from Baseline in Second Phase Total ISR

    Change from baseline in second phase total ISR

    Time frame: Baseline, Week 28

  5. Change from Baseline in Total ISR

    Change from baseline in total ISR

    Time frame: Baseline, Week 28

  6. Change from Baseline in Insulin Response to Arginine [Incremental Insulin Area Under the Curve (AUC) arginine, 0-10minutes]

    Change from baseline in insulin response to arginine \[Incremental Insulin AUC arginine, 0-10minutes\].

    Time frame: Baseline, Week 28

  7. Change from Baseline in Insulin Response to Arginine (Incremental Insulin AUC arginine, 0-30minutes)

    Change from baseline in insulin response to arginine (Incremental Insulin AUC arginine, 0-30minutes).

    Time frame: Baseline, Week 28

  8. Change from Baseline in Beta-cell (β-cell) Glucose Sensitivity (GS)

    Change from baseline in β-cell GS.

    Time frame: Baseline, Week 28

  9. Change from Baseline in β-cell Glucose Sensitivity (GS) from Standardized Mixed-Meal Tolerance Test (sMMTT)

    Change from baseline in β-cell GS from sMMTT.

    Time frame: Baseline, Week 28

  10. Change from Baseline in ISR at Fixed Glucose Concentration (ISRg) from sMMTT

    Change from baseline in ISR at fixed glucose concentration (ISRg) from sMMTT

    Time frame: Baseline, Week 28

  11. Change from Baseline Fasting Glucose During sMMTT (Total and Incremental AUC0-240min)

    Change from baseline fasting glucose during sMMTT (total and incremental AUC0-240min)

    Time frame: Baseline, Week 28

  12. Change from Baseline Postmeal Glucose During sMMTT (Total and Incremental AUC0-240min)

    Change from baseline postmeal glucose during sMMTT (total and incremental AUC0-240min)

    Time frame: Baseline, Week 28

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jan 2027, 19 months after the start.

Of 171 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 10. This study's planned 19 months is above that.

Counting every sponsor, half of 247 studies reached it within 7 months; a quarter within 3 and three quarters within 17.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: primary completion Dec 2026 → Jan 2027 and completion Dec 2026 → Jan 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2025
First posted
May 21, 2025
StartActual
Jun 2, 2025
Primary completionEst.
Jan 2027was Dec 2026
CompletionEst.
Jan 2027was Dec 2026
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 2026→Jan 2027
Oct 6, 2026
Study completion
Dec 2026→Jan 2027
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Primary completion Dec 2026→Jan 2027
    Study completion Dec 2026→Jan 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06982859
Responsible party
Sponsor
First posted
May 21, 2025
Start date
Jun 2, 2025
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Oct 6, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Retatrutide

Start the discussion